http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 08:02:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Fresenius+Medical+Care+launches+cloud+analytics+tool+for+ICU+kidney+care/26787343.html <p>Fresenius Medical Care (NYSE: FMS) has introduced TherapyWise™, a cloud-based analytics capability integrated within its NxView™ 4.0 software platform, which is FDA 510(k)-cleared for use with the NxStage® System One™ in the United States.</p><p>According to a company statement, TherapyWise aggregates therapy and device data generated during kidney replacement therapy (KRT) in acute and hospital critical care settings, presenting program-level metrics in longitudinal summaries. These metrics include average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends.</p><p>The platform transmits data from the NxStage System One with NxView to a cloud-based environment, where information is displayed http://www.streetinsider.com/Corporate+News/Fresenius+Medical+Care+launches+cloud+analytics+tool+for+ICU+kidney+care/26787343.html Mon, 20 Jul 2026 08:02:09 -0400 FMS http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/Press+Releases/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html <div class="xn-content"> <ul type="disc"><li>Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings</li><li>Available within NxStage® System One™ with NxView™ 4.0, <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care's</span> FDA 510(k)-cleared software platform for kidney replacement therapy in <location value="LC/us" idsrc="xmltag.org" >the United States</location></li><li>Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability</li></ul><p><span class="legendSpanClass">BAD HOMBURG, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:3787975393" idsrc="xmltag.org" >Fresenius Medical Care</span>, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of http://www.streetinsider.com/PRNewswire/Fresenius+Medical+Care+introduces+TherapyWise%E2%84%A2+analytics+for+kidney+replacement+therapy/26787222.html Mon, 20 Jul 2026 08:00:00 -0400 A.37879753 FME FMS O.00185691 O.00276450 http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Morgan Stanley analyst Robert Davies lowered the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR33.00) while maintaining a Underweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co.+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Lowered+to+EUR32+at+Morgan+Stanley/26786152.html Mon, 20 Jul 2026 04:59:25 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Citi analyst Veronika Dubajova raised the price target on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) to EUR41.00 (from EUR40.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+PT+Raised+to+EUR41+at+Citi/26781263.html Fri, 17 Jul 2026 04:56:13 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Intl+Ratings/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/New+Coverage/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html <p>Bernstein SocGen Group analyst Susannah Ludwig initiates coverage on Fresenius Medical Care AG & Co KGaA (FME:GR) (NYSE: FMS) with a Market Perform rating and a price target of EUR44.65.</p><p>The analyst comments: “We are initiating on Fresenius Medical Care (“FMC”), the global leader in dialysis services and products with a Market-Perform (PT, EUR 44.65). Dialysis, particularly in the U.S., where FMC is over-indexed, has been a challenged end-market. COVID-19 and its aftermath increased mortality in the vulnerable dialysis and precursor Chronic Kidney Disease (“CKD”) populations, while drugs like SGLT-2s and GLP-1s have slowed progression from CKD into end-stage renal disease http://www.streetinsider.com/Analyst+Comments/Bernstein+SocGen+Group+Starts+Fresenius+Medical+Care+AG+%26+Co+KGaA+%28FME%3AGR%29+%28FMS%29+at+Market+Perform/26775447.html Thu, 16 Jul 2026 02:30:43 -0400 FMS